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Background: While biomarkers for chronic fatigue syndrome (CFS) are beginning to emerge they typically require
a highly specialized clinical laboratory. We hypothesized that subsets of commonly measured laboratory markers
used in combination could support the diagnosis of post-infectious CFS (PI-CFS) in adolescents following infectious
mononucleosis (IM) and help determine who might develop persistence of symptoms.
Methods: Routine clinical laboratory markers were collected prospectively in 301 mono-spot positive adolescents,
4 % of whom developed CFS (n = 13). At 6, 12, and 24 months post-diagnosis with IM, 59 standard tests were
performed including metabolic profiling, liver enzyme panel, hormone profiles, complete blood count (CBC),
differential white blood count (WBC), salivary cortisol, and urinalysis. Classification models separating PI-CFS from
controls were constructed at each time point using stepwise subset selection.
Results: Lower ACTH levels at 6 months post-IM diagnosis were highly predictive of CFS (AUC p = 0.02). ACTH
levels in CFS overlapped with healthy controls at 12 months, but again showed a trend towards a deficiency at
24 months. Conversely, estradiol levels depart significantly from normal at 12 months only to recover at 24 months
(AUC p = 0.02). Finally, relative neutrophil count showed a significant departure from normal at 24 months in CFS
(AUC p = 0.01). Expression of these markers evolved differently over time between groups.
Conclusions: Preliminary results suggest that serial assessment of stress and sex hormones as well as the relative
proportion of innate immune cells measured using standard clinical laboratory tests may support the diagnosis of
PI-CFS in adolescents with IM.
Keywords: Blood glucose, ACTH, Estradiol, Neutrophil count, Free thyroxin, Salivary cortisol, Classification models,
Infectious mononucleosis, EBV, Chronic fatigueBackground
Chronic Fatigue Syndrome (CFS) is a complex, multi-
symptom illness involving persistent fatigue, musculo-
skeletal symptoms, as well as cognitive impairment [1].
Studies show that CFS affects between 1 and 4 million
individuals [2, 3] and costs an estimated $35 billion per
year in health care and lost productivity [4, 5]. CFS af-
fects roughly 0.2 % of the general adolescent population
[6] and is a major cause of educational disruption
[7–10]. While viral serology is not necessary for
diagnosis, CFS follows infection in at least a subset* Correspondence: gbroderick@nova.edu
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(http://creativecommons.org/publicdomain/zeof cases [1, 11]. In adults, symptom onset coincided
with apparent infection in up to 72 % of cases; [12] in ado-
lescents, infectious mononucleosis (IM) is the most com-
monly reported antecedent infection [9, 13–15]. The
reported incidence of CFS following IM is 9-12 % [16–19].
Females appear more susceptible than males [10, 16, 20,
21]. Consistent with this, our group reported previously
that 13, 7 and 4 % of adolescents met criteria for CFS at 6,
12 and 24 months respectively post-IM, and at 6 months
post-IM, 90 % of the subjects with CFS were female, while
at 12 and 24 months, 100 % were female [22].
Diagnosis of CFS currently relies on exclusion of other
medical or psychological causes [1, 23, 24]. Currently
there are no validated diagnostic test, although Klimas
et al. [25] have reviewed some candidate biomarkers.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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[26] and Fletcher et al. [27] found natural killer (NK) cell
cytotoxicity to be low. Fletcher et al. [28] also found evi-
dence that Neuropeptide Y, an immunologically active
neurotransmitter, was elevated in subjects with CFS and
correlated with symptom severity. Mild hypocortisolism
with attenuated diurnal variation has also been reported
in some patients with CFS [29]. In addition to the early
identification of potential individual candidate markers,
studies using multiplex methods have reported broader
surveys and more detailed analyses. For example, while
Curriu et al. [30] found similar cell counts for T, B, and
NK cell populations in general in healthy individuals and
subjects with CFS (n = 22), the latter showed significant
increases in the T-helper and regulatory T cell subsets.
NK cells also showed higher levels of specific activation
markers (e.g., CD69). Suggesting altered patterns of im-
mune signaling, Broderick et al. [31] found that a subset
of 5 cytokines used in combination supported an accur-
acy of better than 80 % at a confidence level of 0.95 in
separating subjects with post-IM CFS versus recovered
controls.
In the present work we focused on common clinical
laboratory assays measured longitudinally to explore
whether a combination of such markers could act as a
signature for CFS following IM. We reviewed commonly
recorded laboratory data collected during a 2-year pro-
spective study of 301 adolescents with mono-spot posi-
tive IM conducted by Katz et al. [22] in the greater
Chicago area. In this study 4 % of subjects met criteria
for CFS per the Jason et al. revision [32] of the Fukuda
criteria [1]. Fifty-nine standard blood, saliva, and urine
tests, such as CBC with differential, metabolic profiling,
and urinalysis, were performed at each time point.
Linear classification models separating post-IM CFS
from controls were constructed at each time point based
on subsets of these markers selected iteratively. While
the vast majority of these markers were uninformative,
changes in ACTH, estradiol, and relative neutrophil
count across the 2-year period were discriminatory for
post-infectious CFS (PI-CFS) with an accuracy ranging
from 72 to 84 %.
Methods
Cohort and clinical assessment
A total of 301 adolescents, ages 12–18, with a diagnosis
of monospot positive acute IM were recruited on a refer-
ral basis from the greater Chicago area via school nurses,
pediatric practices, and the Virology Laboratory of
Children’s Memorial Hospital (now the Ann & Robert H
Lurie Children’s Hospital of Chicago) between Septem-
ber of 2004 and November of 2007. The presumption
was that most cases of monospot-positive acute IM were
caused by Epstein-Barr virus (EBV) infection. Of the 301initially enrolled, 286 adolescents who were not fully re-
covered as well as those who recovered uneventfully
(controls) successfully completed the telephone-based
interview using the CFS Screening Questionnaire [33]
and underwent evaluation at 6, 12, and 24 months post-
IM. Of these subjects, 13, 7, and 4 % (n = 13) respect-
ively met the Jason et al. revision [32] of the Fukuda [1]
case definition for CFS. The former also incorporates
elements of the Canadian case definition reported in
Carruthers et al. [23]. Ninety percent of subjects who
met the CFS case definition at 6 months were female,
and at 12 and 24 months, 100 % of subjects who met
the case definition were female. At 6, 12, and 24 months
post-IM, blood, saliva, and urine samples were collected
from cases and controls for laboratory analysis. Details
of the full cohort are reported in Katz et al. [22]. In the
present study we focus on the specific subset of 13 fe-
male adolescents, representing 4 % of the initial cohort
of over 300 adolescents, who fit the case definition of
CFS at 6, 12 and 24 months following diagnosis with
IM. These adolescents were compared to n = 12 female
control subjects, case-matched on the basis of gender,
age (+/− 1 year, with 1 exception) and Tanner breast and
pubic hair stage (4 or 5, with one exception), who recov-
ered normally following the same infection. All subjects
were menarchal. None of the patients were on signifi-
cant, chronic medications. Five were on no medications.
Four reported occasional inhalers for asthma, or Advil.
Three were on birth control. One patient was on me-
thylphenidate (Concerta), one had a history of clonidine
use in the past and one reported 1 or 2 doses of Xanax
per year because of fear of flying.
Ethics statements
All aspects of the study were approved by the Institutional
Review Boards of Children’s Memorial Research Center
(now the Stanley Manne Research Institute) and the
College of Applied Sciences of the University of Illinois at
Chicago. Written informed consent was obtained from all
participants age 18 years or older. For those subjects less
than 18 years of age, written informed consent was ob-
tained from their guardians, coupled with mandatory child
assent. Secondary analysis of the biological samples and
data was reviewed and approved by the Institutional
Review Board of the University of Alberta.
Laboratory measurements
Morning fasting blood samples were collected into ethyl-
ene diamine tetra acetic acid (EDTA) anticoagulant
tubes from cases and controls at 6, 12, and 24 months
following the diagnosis of monospot positive, acute IM.
Where appropriate plasma was separated within 2 h of
collection and stored at -80oC until assayed. A total of
59 standard laboratory tests were performed according
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and urine, including complete blood count with differen-
tial, metabolic profiling, erythrocyte sedimentation rate,
liver enzymes, thyroid, adrenal, and sex hormone pro-
filing, and urinalysis. Cortisol was isolated from pas-
sive drool with a solid phase extraction protocol
using a Micromass Quattro Micro triple-quadrupole
mass spectrometer equipped with a Z-spray ion source
and a Waters 2795 Alliance HT HPLC system as de-
scribed in Katz et al. [34] Summary statistics for the ex-
pression of these markers are shown in Additional file 1:
Tables S1a-d.
Statistical analyses
To assess the significance of changes in the mean ex-
pression of individual markers occurring across each of
these patient groups versus recovering controls, we used
a standard parametric t-test after performing a logarith-
mic transformation. In conjunction with this, a nonpara-
metric Wilcoxon rank-sum test was used to compare the
difference in group-wise median expression for each
marker at each time point. The significance of the effects
for time and time x group interactions were assessed
using a conventional 2-way ANOVA and verified further
using a regression-based repeated measures analysis.
These calculations were performed using the annovan as
well as the fitrm and ranovatbl functions available in
the MatLab Statistics Toolbox (The MathWorks, Inc.,
Natick, MA).
Individual markers were assessed using different la-
boratory assays. In conventional multiple testing prob-
lems this heteroscedasticity or non-uniform variance can
be removed by rescaling. However, when the null hy-
pothesis involves correlated markers as it does here,
such a rescaling step is known to distort the result and
methods to address this issue still constitute an active
field of research [35]. Thus, raw null probability p-values
are more appropriate in this situation determining the
significance of group-wise changes. Nevertheless, we es-
timated false discovery rates (FDR) using both the more
exploratory measure proposed by Storey [36] and the
more conservative measure of Benjamini and Hochberg
[37]. In the case of the Storey [36] FDR, we estimated
the tuning parameter lambda (λ) using both a bootstrap
method and a polynomial regression. We found the lat-
ter to support more conservative estimates of FDR in
this data set. FDR calculations were performed using the
mafdr function available in the MatLab Statistics
Toolbox (The MathWorks, Inc., Natick, MA).
In addition, we examined patterns of expression in
multiple markers at the level of individual subjects to
address the non-homogeneous nature of these groups.
This was done by constructing linear discriminant
classification models using a stepwise feature selectionmethod to mitigate the effect of cross-correlation be-
tween markers [38]. Such regression models favor
marker subsets that are minimally redundant [39].
Model terms were selected sequentially based on their
respective partial-F test values. Markers with a null
probability p(partial F) < 0.05 were selected for recruit-
ment into the regression model while those currently in
the model but showing a revised p(partial F) > 0.10 were
removed. In the resulting model, an observed row ×
from the sample set is classified into group I rather than
group J if 0 < B0 + x*B, where the coefficient vector B
and intercept vector B0 are estimated from the data. All
markers were normalized a priori using a conventional
z-score to a mean value of 0 and a variance of 1.0 with
observations at 6 months serving as the reference
datum. Classifiers were evaluated based on their over-
all error rate (incorrectly classified/total classified) in
assigning subjects to their proper diagnostic group.
Detection sensitivity and assignment specificity were
then computed over a range of threshold values B0 to
produce a receiver-operator characteristic (ROC) curve
[40]. These calculations were performed using the classify,
classperf, rankfeatures and randfeatures functions avail-
able in the MatLab Statistics Toolbox and the MatLab
Bioinformatics Toolbox (The MathWorks, Inc., Natick,
MA) as well as with the SPSS Statistics Release 21.0 soft-
ware package (IBM, New York, NY). For a further intro-
duction and review of these statistical measures as they
might apply more to clinical practice we refer the reader
to [41, 42].
Results
The results of the parametric t-tests and nonparametric
Wilcoxon rank-sum tests performed on all standard
blood work, salivary tests, and urinalysis measures are
presented in Additional file 1: Tables S1a-d. At 6 months,
those with PI-CFS were found to have depressed glucose
(p= 0.03, ranksum p= 0.05) and depressed ACTH (p= 0.01,
ranksum p= 0.02) compared with controls. At 12 months,
those with PI-CFS were found to have depressed estradiol
compared with controls (p = 0.01, ranksum p = 0.02),
and at 24 months, those with PI-CFS had higher
levels of neutrophils compared with controls (p =0.02,
ranksum p = 0.01). Although this did not meet statistical
significance, we also found elevated free thyroxine (T4) at
both 6 (p = 0.07) and 12 months (p = 0.08). In this group-
wise comparison conducted separately at each time point
none of the p-values obtained, whether by t test or rank-
sum test, corresponded to a FDR of less than 0.20. This
suggests that if values are considered independent from
one visit to the next the probability of an incidental find-
ing is high. However when analyzing the full time course
using a 2-way ANOVA (Additional file 2: Table S2), we
found a significant group effect for elevated free thyroxine
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pressed morning salivary cortisol (p = 0.03; FDR = 0.02,
FDR BH = 0.29) as well as significant time (p = 0.01;
FDR = 0.02, FDR BH = 0.11) and group effects for
ACTH (p = 0.01; FDR = 0.03, FDR BH = 0.26). All three
of these markers, namely free thyroxine (T4), morn-
ing salivary cortisol and ACTH demonstrated group
effects that satisfied a FDR < 0.05 based on Storey
[36] using a polynomial estimate for the tuning factor
lambda (λ). In none of the markers studied were we
able to find a change in the slope of the trend from
one subject group to the next (i.e., time × group ef-
fect). These results were largely confirmed when per-
forming a complementary analysis using a regression-
based repeated measure model (Additional file 3:
Tables S3a - d) with the exception of a few minor
differences in the significance of the time effect only.
Once again no significant time x group effects were
identified.
When linear regression models were applied, one vari-
able, unique at each time point, was selected as being
the most suitable to distinguish between individuals re-
covering normally and those who progressed to PI-CFS.
At 6, 12, and 24 months, ACTH, estradiol, and neutro-
phils, respectively, were highly discriminatory for PI-
CFS. As shown in Table 1, at 6 months, the model based
on depressed ACTH levels produced an accuracy of
72 %, a negative predictive value (NPV) of 73 %, positive
predictive value (PPV) of 71 %, specificity of 67 %, and
sensitivity of 77 %. In comparison, low glucose levels
supported a slightly higher PPV (75 %) and specificity
(75 %), but lower NPV (69 %) and sensitivity (69 %).
Similarly at 12 months, the model based on depressed
estradiol alone produced an accuracy of 76 %, a NPV ofTable 1 Identification and performance of linear classification mode
subjects at 6, 12 and 24 months post-diagnosis with IM using linear
time point based on classical stepwise variable selection with the ex
which was specified based on differential expression
Model Assigned RC Assigned PI-FS Total
6 months
ACTH 8 4 12 True R
3 10 13 True P
Glucose 9 3 12 True R
4 9 13 True P
12 months
Estradiol 9 3 12 True R
3 10 13 True P
24 months
Neutrophils 10 2 12 True R
2 11 13 True P75 %, a PPV of 77 %, with a specificity of 75 %, and a
sensitivity of 77 %. The classification accuracy increases
as the sample time approaches 24 months. When ap-
plied to subject classification at 24 months, the model
based on increased neutrophil count produced an accur-
acy of 84 % corresponding to a NPV of 83 %, PPV of
85 %, specificity of 83 %, and sensitivity of 85 %.
Table 2 shows a summary of receiver operating charac-
teristic (ROC) performance for classification of PI-CFS
subjects at 6, 12, and 24 months post-diagnosis of IM
using linear discriminant models with terms selected as
optimal at each time point. Classification for the even-
tual onset of post-IM CFS at the 2-year time point based
on ACTH levels measured at 6 months produced an
area under the curve (AUC) of 0.77 (p = 0.02). In com-
parison, glucose measured at 6 months only supports an
AUC value of 0.73 (p = 0.05). Estradiol levels measured
at 12 months produced a classification for illness at
24 months with an AUC value of 0.78 (p = 0.02). Finally,
illness at 24 months was predicted based on the relative
level of neutrophils at that same time point with a highly
significant value for the AUC of 0.83 (p = 0.01). The
ROC curves produced based on measures taken at each
time point are presented in Fig. 1 for the markers se-
lected by stepwise regression, namely ACTH, estradiol
and relative neutrophil count. The evolution across the
2-year period of all 4 differentially expressed markers is
presented in Fig. 2.
Discussion
The diagnosis of CFS currently relies on the exclusion of
other medical and psychiatric diseases. We sought to de-
termine if standard laboratory analysis of blood, salivary,
and urine markers used alone or in combination mightls. Classification of PI-CFS and healthy recovered control (RC)
discriminant models with terms identified as optimal at each
ception of classification based on glucose levels at 6 months
Accuracy NPV PPV Specificity Sensitivity
C 0.72 0.73 0.71 0.67 0.77
I-CFS
C 0.72 0.69 0.75 0.75 0.69
I-CFS
C 0.76 0.75 0.77 0.75 0.77
I-CFS
C 0.84 0.83 0.85 0.83 0.85
I-CFS
Table 2 Summary of receiver operating characteristic (ROC) performance. Area under the classification curve (AUC) for assignment
of PI-CFS subjects at 6, 12 and 24 months post-diagnosis with IM using a linear discriminant models with terms selected as optimal
at each time point using s stepwise selection method. Classification performance based on glucose levels measured at 6 months is
included for comparison and was specified on the basis of t and ranksum tests
Area Std. errora Asymptotic Sig.b Asymptotic 95 % Conf. interval
Model Lower bound Upper bound
ACTH (6 months) 0.77 0.10 0.02 0.58 0.96
Glucose (6 months)c 0.73 0.11 0.05 0.52 0.95
Estradiol (12 months) 0.78 0.09 0.02 0.60 0.97
Neutrophil (24 months) 0.83 0.09 0.01 0.64 1.00
The test result variable(s): acth1 has at least one tie between the positive actual state group and the negative actual state group. Statistics may be biased
aUnder the nonparametric assumption
bNull hypothesis: true area = 0.5
cModel specified on the basis of t and ranksum tests, not as a result of stepwise selection
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PI-CFS. In the adolescent population studied we found
significantly lower levels of glucose and ACTH 6 months
following IM in individuals who 18 months later would
continue to suffer with persistent symptoms. Glucose
was not selected as a distinguishing variable using step-
wise regression even though it displayed similar predict-
ive power because of a strong overlap with similar
changes in ACTH. Changes in glucose homeostasis
during infection are context-dependent and poorly
understood [43] with cytokines such as IL-6 reportedlyFig. 1 Performance of subject classification based on a minimal set of stan
on to develop post-infectious chronic fatigue syndrome and subjects who
optimal based on data collected at 6, 12 and 24-month time points using
collected at each time point onlypromoting hypoglycemia during acute LPS-induced in-
flammation [44]. Interestingly relative expression of the
latter emerged as a distinguishing feature for this illness
group in our previous work [31]. In addition, signifi-
cantly lower levels of estradiol and increased relative
neutrophil count were also observed 12 and 24 months
post-IM (Table 1). The accuracy of each individual
marker in identifying individuals who develop PI-CFS at
24 months ranged between 72-84 %. The fact that
different markers discriminated better at different times
might highlight the dynamic nature of the immune anddard clinical assays. ROC curves for classification of subjects who went
recovered normally using a linear discriminant model selected as
a stepwise selection method. Coefficients were tuned based on data
Fig. 2 Time course progression in expression of key discriminatory makers. Evolution of ACTH concentration (a), glucose concentration (b),
estradiol concentration (c) and neutrophil count (d) in blood collected at 6, 12 and 24 months post-diagnosis with IM in subjects who went on
to develop post-infectious chronic fatigue syndrome (PI-CFS; red square) and normally recovered control subjects (RC; blue triangle)
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acterized as progressive. In several markers a persistent
offset appears to be acquired quite early however the
nonlinear nature of these changes is not easily captured
by traditional linear analysis, e.g., the 2-way ANOVA
employed herein. Because of this, single assessments will
be of limited value while serial assessments within the
first year may be much better suited for aiding in diagno-
sis of these subjects (e.g., serial estradiol measurements).
CFS is a complex constellation of symptoms [25].
Cannon et al. [45] found sex hormone driven changes in
neutrophil count characteristic of CFS. The latter re-
ported that while neutrophil count normally increases
from the follicular to luteal phase in healthy women, it
persists at luteal levels in CFS. Niblett et al. [46] also
found that the neutrophil count and ratio of neutrophils
to lymphocytes were both increased in CFS subjects.
Discrepancies in neutrophil function have also beenobserved in some subjects with CFS with an overabun-
dance of pre-apoptotic cells [47, 48]. Significant alter-
ations in NK cell signaling and function have also been
observed in some populations with CFS such as in our
previous work in older women, where the elimination of
target erythroleukemic K562 cells by NK cells was sig-
nificantly impaired in CFS [27]. However Katz et al. [34]
studying a similar population to that reported here
found normal NK cell number and function in adoles-
cents with CFS following IM. In addition to differences
in the ages of the subjects between the two previously
cited studies, there were also differences in methodology;
the latter assessed cytotoxic function of NK cell isolates
while the former studied NK cell function in a mixed
lymphocyte population.
Involvement of sex-hormones in CFS is also consistent
with our earlier work [49] and that of others, in which
women were significantly more affected by this illness
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theoretical model of regulatory physiology linking
the hypothalamic-pituitary-adrenal (HPA) axis, the
hypothalamic-pituitary-gonadal (HPG) and the per-
ipheral immune system have shown that these inter-
acting systems are especially prone in women to
support chronically depressed cortisol levels and a
persistent inflammatory signature consistent in some
CFS populations [50].
Dysregulation of normal hypothalamic-pituitary-
adrenal (HPA) axis function has been reported previ-
ously in patients with CFS [51]. Again, in our previous
study from this population, we found no evidence of
consistently depressed salivary cortisol in adolescents
with CFS compared with recovered controls when indi-
vidual time points were compared, although 3 of 9 sub-
jects with CFS did have depressed morning cortisol
(versus 1 of 9 controls). We concluded that depressed
salivary cortisol may be an uncommon factor in CFS as
even in those cases where it might play a role it did not
persist despite persistence of symptoms [34]. In the
current report, we found evidence of a group effect for
depressed morning salivary cortisol as well as possibly
other elements of hypothalamic-pituitary-thyroid (HPT)
dysregulation with elevated free T4 at both 6 (p = 0.07)
and 12 months (p = 0.08), which trended towards signifi-
cance. These findings are also consistent with Fuite et al.
[52] who found evidence of re-modeling in neuro-
endocrine and immune signaling in CFS. Specifically,
results suggested a decreased cohesiveness in HPA axis
response that coincided with a characteristic co-
expression of immune markers with thyroid hormones
in a larger group (n = 39) female CFS subjects. Changes
in HPA axis feedback dynamics have also been reported
recently by Aschbacher et al. [51] who describe an ab-
normal increase in negative feedback along the HPA axis
in CFS. If examined individually, the observed decreases
in these markers, while statistically significant, may es-
cape biological significance. For example, estradiol levels
from 10 to 260 are all normal for either the luteal or fol-
licular phases of the menstrual cycle. Our study is an ad
hoc analysis of prospectively collected data. If confirmed
prospectively, depressed ACTH and possibly glucose
might offer an objective way to confirm the diagnosis of
CFS at 6 months following IM, while persistence of in-
creased T4 and decreased morning salivary cortisol
coupled with decreased estradiol at 12 months and in-
creased neutrophil counts at 24 months might provide
objective evidence for the persistence of CFS. Whether
any of these findings would be helpful earlier than
6 months following IM is not known.
Limitations of this exploratory study include the small
number of subjects (n = 13) and the relatively coarse
sampling interval; nonetheless these were prospectivelycollected data from a study of PI-CFS with a well-
defined trigger (IM). While these findings may not be
applicable to the entire CFS population, a significant
subset thereof reports onset coinciding with infectious
illness. Though it is necessary validate these findings in a
larger cohort, these initial results support the potential
opportunity to identify individuals most at risk for devel-
oping CFS following IM and who might benefit from a
more pro-active treatment. We purposely limited our as-
sessment to common clinical markers in blood, saliva,
and urine; while these readily available tests may not
have the resolution to make a diagnosis, they may be
sufficiently robust to support one. Indeed, additional
means of confirmation using more focused laboratory
assays as well as physiologic challenges to amplify these
differences are being studied [53]. For example, in apply-
ing a maximal exercise challenge to this cohort our
group found significantly higher oxygen consumption,
work slope, and peak oxygen pulse in recovered subjects
versus patients diagnosed with PI-CFS at 6 months after
IM [54]. Other groups are reporting that such differ-
ences increase several fold in a follow-up challenge per-
formed 24 h later [55] suggesting that a stress test may
be much more revealing than a standard assessment.
These limitations not withstanding, we found evidence
that the onset of PI-CFS may be associated with the ex-
pression of specific patterns of markers in standard
blood work. Whether these markers are etiologically re-
lated to CFS also remains to be determined and further
studies should include at least one comparator illness
common to this age group.
Conclusions
In a first exploratory analysis of a clinical data set we
found that assessment of stress and sex hormones as well
as the relative proportion of innate immune cells using
standard clinical laboratory tests may help support the
diagnosis of PI-CFS in adolescents with IM. Specifically,
early course deviations in ACTH and possibly glucose
along with subsequent differences in the levels of morning
salivary cortisol, T4 and estradiol might provide objective
evidence for the onset and persistence of CFS. As the rela-
tive deviations in these markers evolve over time, their
contribution to accuracy and robustness of classification is
greatly improved if they are recorded longitudinally.
Additional files
Additional file 1: Table S1a. Summary descriptive statistics of clinical
assays. Mean and standard deviation () of the conventional complete
metabolic profiling in blood at 6, 12 and 24 months following diagnosis
with IM. Table S1b. Summary descriptive statistics of clinical assays. Mean
and standard deviation () of the conventional complete blood count
(CBC) profiling in blood at 6, 12 and 24 months following diagnosis with
IM. Table S1c. Summary descriptive statistics of clinical assays. Mean and
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profiling in blood at 6, 12 and 24 months following diagnosis with IM.
Basophil count was not considered due to a large proportion of missing
values. Table S1d. Summary descriptive statistics of clinical assays. Mean
and standard deviation () of the conventional endocrine profiling in
blood with urine specific gravity and pH at 6, 12 and 24 months
following diagnosis with IM. (DOC 149 kb)
Additional file 2: Table S2a. Summary of 2-way ANOVA. Significance
of time, group and time x group effects of conventional metabolic
profiling in blood across 6, 12 and 24 months following diagnosis with
IM. False discovery rates (FDR) were based on Storey [36] using the
bootstrap (boot) and the polynomial (poly) fit methods to estimate
lambda, as well as on by Benjamini and Hochberg [37] (BH). Table S2b.
Summary of 2-way ANOVA. Significance of time, group and time x group
effects for complete blood count (CBC) profiling in blood across 6, 12
and 24 months following diagnosis with IM. False discovery rates (FDR)
were based on Storey [36] using the bootstrap (boot) and the polynomial
(poly) fit methods to estimate lambda, as well as on by Benjamini and
Hochberg [37] (BH). Table S2c. Summary of 2-way ANOVA. Significance
of time, group and time x group effects for conventional differential
blood count profiling in blood across 6, 12 and 24 months following
diagnosis with IM. False discovery rates (FDR) were based on Storey [36]
using the bootstrap (boot) and the polynomial (poly) fit methods to
estimate lambda, as well as on by Benjamini and Hochberg [37] (BH).
Basophil count was not considered due to a large proportion of missing
values. Table S2d. Summary of 2-way ANOVA. Significance of time, group
and time x group effects for standard endocrine profiling in blood with
urine specific gravity and pH across 6, 12 and 24 months following
diagnosis with IM False discovery rates (FDR) were based on Storey [36]
using the bootstrap (boot) and the polynomial (poly) fit methods to estimate
lambda, as well as on by Benjamini and Hochberg [37] (BH). (DOC 150 kb)
Additional file 3: Table S3a,b,c and d. Supplemental tables containing
summary statistics describing the significance and probability of false
discovery for the effects of time and the time x group interaction for each
of the clinical markers using a regression-based repeated measures model.
(XLSX 48 kb)
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